Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2426-2427, 2005; 10.1373/clinchem.2005.058552
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bossuyt, X.
Right arrow Articles by Luyckx, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bossuyt, X.
Right arrow Articles by Luyckx, A.
Related Collections
Right arrow Clinical Immunology
(Clinical Chemistry. 2005;51:2426-2427.)
© 2005 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Antibodies to Extractable Nuclear Antigens in Antinuclear Antibody–Negative Samples

Xavier Bossuyta and Ariane Luyckx

Laboratory Medicine, Immunology, University Hospital Leuven, Leuven, Belgium

aAddress correspondence to this author at: Department of Laboratory Medicine, Immunology, University Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium. Fax 32-13-347042; e-mail xavier.bossuyt@uz.kuleuven.ac.be.

The first 20% of the full text of this article appears below.


To the Editor:

Antibodies to extractable nuclear antigens (ENAs)—SSA, SSB, U1RNP, Sm, Scl-70, and Jo-1—are clinically important in patients with systemic rheumatic diseases. Indirect immunofluorescence (IIF) with HEp-2 cells is a common initial screening test for detection of antinuclear antibodies (ANAs) and antibodies to ENAs. IIF-positive samples are further screened with more specific assays, but few studies have addressed the value of this cascade testing (1)(2). Although screening with conventional HEp-2 cells may miss some antigens, such as SSA (3) and Jo-1(4), false-negative ANA results are infrequent (1)(2). SSA-transfected cells in particular, which overexpress SSA (60 kDa), are considered highly sensitive for detection of anti-SSA antibodies (5). Some antibodies to ENAs can be missed by IIF, however (6). Hoffman et al. (6) found that of 291 ANA-negative samples, 12 were positive for antibodies to ENAs, including antibodies to SSA (Ro52 and Ro60), SSB, . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 LupusHome page
S. Binder
Autoantibody Detection Using Multiplex Technologies
Lupus, July 1, 2006; 15(7): 412 - 421.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.